Transcatheter aortic valve replacement in patients with severe mitral or tricuspid regurgitation at extreme risk for surgery
Stephen H. Little(Houston Methodist), Michael J. Reardon(Houston Methodist), Stan Checuti(University of Michigan), Neal S. Kleiman(Houston Methodist), B. Jane Moore(Medtronic (United States)), George Petrossian, John Heiser(Corewell Health), Thomas G. Gleason(Asheville Cardiology Associates), Tanvir Bajwa(Aurora Health Care), Daniel O’Hair(UPMC Health System), N. Bryce Robinson, Jeffrey J. Popma(Cardiovascular Research Foundation), Stanley Katz(North Shore University Hospital), David Adams(Mount Sinai Health System), Shuzhen Li(Hubei University of Medicine), William Merhi(Corewell Health), Alan Hartman(North Shore University Hospital), G. Michael Deeb(University of Michigan), Steven J. Yakubov(OhioHealth), Mubashir Mumtaz(University of Pittsburgh Medical Center), Brijeshwar Maini(Florida Atlantic University)
Cited by 15
Related Papers
Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients
|New England Journal of Medicine|2019|3.6k
Stenting versus Endarterectomy for Treatment of Carotid-Artery Stenosis
|New England Journal of Medicine|2010|3k
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Protected Carotid-Artery Stenting versus Endarterectomy in High-Risk Patients
|New England Journal of Medicine|2004|2.9k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k